Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis.

Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL, Valgimigli M, Bhatt DL, Mauri L, Charytan DM.

Clin J Am Soc Nephrol. 2019 Apr 22. pii: CJN.12901018. doi: 10.2215/CJN.12901018. [Epub ahead of print]

PMID:
31010936
2.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMoa1811744. [Epub ahead of print]

PMID:
30990260
3.

Relationship between dialytic parameters and reviewer confirmed arrhythmias in hemodialysis patients in the monitoring in dialysis study.

Tumlin JA, Roy-Chaudhury P, Koplan BA, Costea AI, Kher V, Williamson D, Pokhariyal S, Charytan DM; MiD investigators and Committees.

BMC Nephrol. 2019 Mar 5;20(1):80. doi: 10.1186/s12882-019-1212-6.

4.

Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.

Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, Parving HH, Parfrey P, Singh AK, Burdmann EA, Levey AS, Eckardt KU, McMurray JJV, Weinrauch LA, Liu J, Claggett B, Lewis EF, Pfeffer MA.

Diabetes Obes Metab. 2019 May;21(5):1199-1208. doi: 10.1111/dom.13642. Epub 2019 Mar 4.

PMID:
30672083
6.

Long-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II Trial.

Lima EG, Charytan DM, Hueb W, de Azevedo DFC, Garzillo CL, Favarato D, Linhares Filho JPP, Martins EB, Batista DV, Rezende PC, Hueb AC, Ramires JAF, Kalil Filho R.

Nephrol Dial Transplant. 2018 Dec 24. doi: 10.1093/ndt/gfy379. [Epub ahead of print]

PMID:
30590726
7.

Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial).

Vaduganathan M, White WB, Charytan DM, Morrow DA, Liu Y, Zannad F, Cannon CP, Bakris GL; EXAMINE Investigators.

Am J Cardiol. 2019 Feb 1;123(3):382-391. doi: 10.1016/j.amjcard.2018.10.035. Epub 2018 Nov 6.

PMID:
30477800
8.

Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.

Charytan DM, Himmelfarb J, Ikizler TA, Raj DS, Hsu JY, Landis JR, Anderson AH, Hung AM, Mehrotra R, Sharma S, Weiner DE, Williams M, DiCarli M, Skali H, Kimmel PL, Kliger AS, Dember LM; Hemodialysis Novel Therapies Consortium.

Kidney Int. 2019 Apr;95(4):973-982. doi: 10.1016/j.kint.2018.08.034. Epub 2018 Nov 23.

PMID:
30473139
9.

Introduction: Cardiovascular Disease in Chronic Kidney Disease.

Charytan DM.

Semin Nephrol. 2018 Nov;38(6):541. doi: 10.1016/j.semnephrol.2018.08.008. No abstract available.

PMID:
30413249
10.

Extracorporeal Stromal Cell Therapy for Subjects With Dialysis-Dependent Acute Kidney Injury.

Miller BLK, Garg P, Bronstein B, LaPointe E, Lin H, Charytan DM, Tilles AW, Parekkadan B.

Kidney Int Rep. 2018 Jun 2;3(5):1119-1127. doi: 10.1016/j.ekir.2018.05.009. eCollection 2018 Sep.

11.

The Authors Reply.

Charytan DM, Roy-Chaudhury P.

Kidney Int. 2018 Aug;94(2):430-431. doi: 10.1016/j.kint.2018.05.012. No abstract available.

PMID:
30031449
12.

End-Stage Renal Disease and Arrhythmic Death.

Weinrauch LA, Charytan DM, D'Elia JA.

JACC Clin Electrophysiol. 2018 Jul;4(7):975-976. doi: 10.1016/j.jacep.2018.04.018. No abstract available.

PMID:
30025702
13.

Echocardiographic parameters and renal outcomes in patients with preserved renal function, and mild- moderate CKD.

Mavrakanas TA, Khattak A, Singh K, Charytan DM.

BMC Nephrol. 2018 Jul 11;19(1):176. doi: 10.1186/s12882-018-0975-5.

14.

Comparative Utilization and Temporal Trends in Cardiac Stress Testing in U.S. Medicare Beneficiaries With and Without Chronic Kidney Disease.

Herzog CA, Natwick T, Li S, Charytan DM.

JACC Cardiovasc Imaging. 2018 Jun 8. pii: S1936-878X(18)30369-3. doi: 10.1016/j.jcmg.2018.04.012. [Epub ahead of print]

PMID:
29909107
15.

Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Eckardt KU, Bansal N, Coresh J, Evans M, Grams ME, Herzog CA, James MT, Heerspink HJL, Pollock CA, Stevens PE, Tamura MK, Tonelli MA, Wheeler DC, Winkelmayer WC, Cheung M, Hemmelgarn BR; Conference Participants.

Kidney Int. 2018 Jun;93(6):1281-1292. doi: 10.1016/j.kint.2018.02.006. Epub 2018 Apr 12.

16.

Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, Kasner SE, Passman RS, Pecoits-Filho R, Reinecke H, Shroff GR, Zareba W, Cheung M, Wheeler DC, Winkelmayer WC, Wanner C; Conference Participants .

Eur Heart J. 2018 Jun 21;39(24):2314-2325. doi: 10.1093/eurheartj/ehy060. No abstract available.

17.

Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle.

Roy-Chaudhury P, Tumlin JA, Koplan BA, Costea AI, Kher V, Williamson D, Pokhariyal S, Charytan DM; MiD investigators and committees.

Kidney Int. 2018 Apr;93(4):941-951. doi: 10.1016/j.kint.2017.11.019. Epub 2018 Feb 12.

18.

Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes.

Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM.

Clin J Am Soc Nephrol. 2018 Mar 7;13(3):398-405. doi: 10.2215/CJN.05280517. Epub 2018 Jan 16.

19.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

20.

Early versus late initiation of renal replacement therapy in patients with acute kidney injury: a meta-analysis of randomised clinical trials.

Mavrakanas TA, Aurian-Blajeni DE, Charytan DM.

Swiss Med Wkly. 2017 Oct 12;147:w14507. doi: 10.4414/smw.2017.14507. eCollection 2017.

Supplemental Content

Loading ...
Support Center